Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today released a… Read More..

Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J., Feb. 9, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it… Read More..

Acquisition payments to include up to 5,223,991 shares of SKYX's common stock and $8 million in cash at close that has been fully funded by two major existing SKYX investors, with an additional $4 million deferred cash payment one year after close MIAMI, FL / ACCESSWIRE / February 7, 2023… Read More..